Global Blood Therapeutics Inc (GBT)

  • Get an in-depth profile of Global Blood Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
68.49 +0.00 (+0.00%)
Close USD Disclaimer

Global Blood Therapeutics Inc Company Profile

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
457
Equity Type
ORD
Global Blood Therapeutics, Inc. engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral once-daily therapy for SCD. It also evaluates pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company develops its lead product candidate inclacumab, a novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises and resulting hospital admissions and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. Global Blood Therapeutics, Inc. was incorporated in 2011 and is based in South San Francisco, California with additional locations in Baar, Switzerland; Paris, France; Berlin, Germany; and London, United Kingdom. As of October 5, 2022, Global Blood Therapeutics, Inc. operates as a subsidiary of Pfizer Inc.
Contact Information
Address
South San Francisco,94080 United States
Phone
650 741 7700
Fax
-
Web
https://www.gbt.com

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles